ENABLE
What it found
No result yet.
What was tested
Treatment tested
- No Intervention
What it measured
Main measures
Annualized Relapse Rate (ARR)
Up to Week 96
Relapses
Other measures (2)
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Up to Week 96
SafetyNumber of Participants with Infusion Related Reaction (IRR) at Each Infusion
Up to Week 96
Safety
Who could take part
Relapsing MS · 18 and over
Inclusion Criteria: 1. Confirmed Multiple Sclerosis (MS) diagnosis. 2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included. Exclusion Criteria: 1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration. 2. Any active infection (e.g., active Hepatitis B virus [HBV]) 3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Loading reviews and guidelines…
History
Started
Jul 2024
Main results due
Apr 2032
Finished
Apr 2032
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error